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Implanted bioengineered livers have not exceeded three days of continuous perfusion. Here, we 
show that decellularized whole porcine livers revascularized with human umbilical endothelial 
cells and implanted heterotopically into immunosuppressed pigs whose spleen has been removed 
can sustain perfusion for up to 15 days. We identified peak glucose consumption rate as a main 
predictor of the patency of the revascularized bioengineered livers (rBELs). On heterotopic 
implantation of the rBELs into pigs in the absence of anticoagulation therapy led to sustained 
perfusion for 3 days, followed by significant immune responses directed against the human 
endothelial cells. A 10-day steroid-based immunosuppression protocol and a splenectomy at time 
of rBEL implantation reduced the immune responses and resulted in continuous perfusion of the 
rBELs for over two weeks. We also show that the human endothelial cells in the perfused rBELs 
colonize the liver sinusoids and express sinusoidal endothelial markers similar to those in normal 
liver tissue. Revascularized liver scaffolds that can maintain blood perfusion at physiological 
pressures might eventually help overcome the chronic shortage of transplantable human livers.
Liver transplantation currently represents the only treatment for end stage liver disease 
(ESLD), though a chronic shortage of viable donor organ material continues to limit the 
number of lifesaving liver transplants that can be performed. Recent advances in tissue 
engineering methods have accelerated the development of bioengineered organs as an 
alternative source of donor material, though the challenge of developing functional 
vasculature to support cellular metabolism, gas-exchange and sustained perfusion in vivo has 
remained a major barrier to the clinical translation of these technologies1. Bioengineered 
liver (BEL) constructs have been created through the recellularization of acellular liver 
scaffolds and have demonstrated in vitro functionality2–8. Short-term in vivo function has 
also been reported following transplantation in small animal models9, though rapid vascular 
thrombosis has limited the duration of in vivo graft patency. Passivation methods and high 
doses of anticoagulants have been employed to extend the in vivo patency of BELs, though 
these approaches have only modestly extended thromboresistance6,10,11. To date, no 
reported methods have demonstrated a capacity to exceed three days of continuous BEL 
perfusion in-vivo.
Decellularized whole liver matrix holds great potential as a technology for developing a 
theoretically limitless supply of functional BELs12,13. While several groups have 
demonstrated an ability to seed a variety of liver-specific cell types into decellularized liver 
constructs12,14–16, reconstituting the endothelial cell lining within the vascular networks in 
these scaffolds has remained a significant challenge to the development of a therapeutic 
BEL17.
Here, we report an optimized method for revascularizing a clinically-scaled porcine liver 
scaffold. Using human umbilical endothelial cells (HUVECs) as a primary cell source, we 
characterized the kinetics of endothelial cell proliferation within decellularized liver 
scaffolds during perfusion bioreactor culture and identified glucose consumption rate (GCR) 
as a reliable metric for non-destructively monitoring cell proliferation, and ultimately 
predicting graft patency upon acute blood perfusion. Histological characterization of 
revascularized bioengineered livers (rBELs) revealed that HUVECs localized within 
sinusoidal regions upregulated expression of LYVE1 and downregulated CD31 expression 
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over time, suggesting a transition toward a liver sinusoidal endothelial cell (LSEC)-like 
phenotype. Transcript analysis of rBEL samples revealed global changes in gene expression 
in grafts with high GCRs, including upregulation of additional LSEC markers, and 
transmission electron microscopy (TEM) revealed the existence of fenestrae-like structures 
in endothelial cells localized within sinusoidal regions. Finally, up to 15 days of continuous 
in vivo rBEL perfusion was achieved under a steroid-based immunosuppression protocol 
following heterotopic implantation in a large animal liver transplant model. Characterization 
of the recipient animal immune response following graft implantation revealed the presence 
of HUVEC-reactive antibodies and identified complement-activation as a likely driver of 
graft rejection and eventual thrombosis. Taken together, this work demonstrates to our 
knowledge the longest-to-date example of in vivo perfusion of a BEL, and establishes a 
method for future recellularization studies aimed at bioengineering a functional liver 
construct for eventual translation into the clinic.
Results
Liver decellularization and perfusion bioreactor culture
Porcine livers utilized in this study were cannulated on the portal vein (PV), infrahepatic 
inferior vena cava (IVC), and suprahepatic vena cava (SVC), and decellularized by 
sequential perfusion with Triton X-100 solutions and sodium dodecyl sulfate (SDS) 
solutions to remove cellular material while preserving the overall architecture of the scaffold 
(Fig. 1a, b, e). Histological sectioning from representative decellularized scaffolds confirmed 
the maintenance of parenchymal liver lobule structures when compared to that of native 
porcine liver tissue (Fig. 1c, f), as well as retention of Collagen I (Fig. 1d, g).
Decellularized liver scaffolds were mounted in custom bioreactors (Fig. 1h, i) and perfused 
with culture media through the SVC at a constant inflow pressure of 12 mmHg at 37°C and 
5% CO2. Following 72 h of continuous media perfusion to precondition the scaffold and 
confirm the absence of viable bioburden, 1.5×108 HUVECs were infused through the 
perfusion circuit into the SVC vasculature (Fig. 2a). Following 24 h of continuous media 
perfusion, liver scaffolds were aseptically manipulated and infused with an additional 
1.5×108 HUVECs through the PV (Fig. 2a). Prior to seeding, purity of the HUVEC cultures 
were confirmed by CD31+ flow cytometry (Fig. 2b). Culture media was continuously 
perfused through the PV at 12 mmHg for the remaining period of bioreactor culture.
Characterization of HUVEC proliferation
To define quantitative markers for non-invasively monitoring endothelial cell proliferation in 
the liver scaffold, a panel of metabolites (glucose, lactate, glutamate, and ammonia) were 
measured daily from a sample of rBEL culture media (data not shown). GCR measured 
throughout the period of bioreactor culture exhibited sigmoidal kinetics in most rBELs and 
could be generally characterized by low (<20 mg/h), mid (20–45 mg/h), and high (>45 
mg/h) GCR phases (Fig. 2c). Histological examination of representative rBELs with low, 
mid, and high GCRs correlated with increasing endothelial cell densities as inferred by H&E 
staining, with evidence of primary engraftment in larger vessels and subsequent expansion 
and migration into the parenchymal or sinusoidal niche at mid and high GCRs (Fig. 2d–f). 
Shaheen et al. Page 3













As a result, rBEL GCRs were utilized as a metric for estimating the extent of graft re-
endothelialization in later parts of this study. During bioreactor culture, media volumes were 
adjusted and replaced daily to maintain steady state glucose levels above 500 mg/L (>50% 
of baseline media concentrations) to ensure consistent proliferation kinetics and discourage 
premature cell senescence due to glucose starvation18. Two rBELs failed to exhibit 
sigmoidal kinetics and achieve a GCR rate >20 mg/h (Fig. 2c) and demonstrated similar 
proliferation kinetics to significantly under seeded rBELs (data not shown), likely a result of 
an undetected hole in the portal or hepatic vein during seeding.
Phenotypic plasticity of HUVECs in rBELs
Immunostaining of rBELs during low, mid and high GCR phases with anti-CD31 and anti-
Collagen I antibodies (Fig. 2g–i, Supplementary Fig. S1a) revealed HUVEC localization 
within vascular structures and overall uniform cell distribution within the decellularized liver 
matrix. Endothelial cell engraftment was primarily localized within larger vessels during the 
low GCR phase following seeding, followed by an increase in cell proliferation within 
sinusoidal regions at mid and high GCR phases. Immunostaining for LYVE1, a marker 
expressed by LSECs, demonstrated highest expression in the parenchymal sinusoids with 
little expression in larger vessels (Fig. 2k–m, Supplementary Fig. S1b) consistent with native 
liver sinusoid staining19. The expression and localization of LYVE1 was weakly detected 
during the low GCR phase and became progressively stronger in the mid and high GCR 
phases. Transcript levels of LSEC-associated markers measured by qRT-PCR at high GCR 
phase demonstrated an upregulation of LYVE1 (7.2-fold +/− 1.8, n=7, mean ± std) and 
STAB2 (4.8-fold +/− 3.31, n=7) compared to HUVEC cells in 2D culture, as well as a 
significant increase from low to high phases (p<0.05) for LYVE1, while CD31 was not 
significantly changed (1.9-fold +/− 1.8, n=7) (Fig. 1j). Global characterization of rBEL 
samples from low and high GCR phases through RNA-seq analysis revealed significant 
changes in gene expression profiles over time as demonstrated by a global principle 
component analysis (Fig. 2n) and targeted similarity analysis using known liver endothelial 
cell markers20 (Fig. 2o, Supplementary Dataset 3). Further analysis of the RNA-seq datasets 
confirmed upregulation of LYVE1, and additionally showed downregulation of VWF and 
upregulation of ICAM1 in high GCR samples (Fig. 2p), revealing additional expression 
trends that resemble recently reported primary human LSEC transcript profiles20.
A hallmark feature of LSECs in normal liver tissue is the presence of plasma membrane 
fenestrations which enable diffusion of nutrients and waste products between the capillary 
vessels and the adjacent parenchymal space. To determine whether endothelial cells 
localized within sinusoids of rBEL constructs exhibited such features, TEM was performed 
on samples from native porcine liver tissue (Fig. 2q) and high GCR phase rBELs (Fig. 2r–t). 
Micrographs from rBELs exhibited fenestrae-like structures similar to those observed in 
native porcine liver sections. The quantified dimensions of these features were consistent 
with those of LSEC fenestrations (100‐150 nm)21. Collectively, these results reveal a new 
dimension of HUVEC phenotypic plasticity22,23 and suggest that distinct 
microenvironments in decellularized liver matrix may have the capacity to direct phenotypic 
differentiation of endothelial cells.
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Peak GCR in rBELs correlates with patency
To assess the patency of rBELs, an ex vivo blood loop circuit utilizing fresh heparinized 
porcine blood was employed (Fig. 3a, c). Using a peristaltic pump, pre-warmed blood 
(37°C) was perfused through the PV of the rBEL and returned to the blood reservoir 
following outflow from the IVC. Perfusion was maintained at a constant pressure of 12 
mmHg and flow rates were monitored over time. Flow rates <50ml/min after 30 minutes 
were deemed inadequate for in vivo perfusion. Evaluation of non-seeded decellularized liver 
scaffolds consistently resulted in flow rates <10 ml/min after 5 minutes and had zero flow 
after 15 minutes (data not shown). Peak glucose consumption rate (PGCR) is the maximum 
GCR measured during BEL culture with rates >30 mg/h in rBELs correlated with sustained 
flow rates >50 ml/min, thereby validating the use of the PGCR as a marker for functional re-
endothelialization of rBELs (n=5) (Fig. 3k). Histological evaluation of low glucose 
consuming grafts following blood perfusion and saline flushing showed blood pooling and 
compaction within the graft, while grafts with PGCRs >30 mg/h were efficiently cleared 
with saline (Supplementary Fig. S2).
To determine the value of PGCR in predicting rBEL patency in vivo, a large animal porcine 
model for auxiliary liver transplantation was established to enable the implantation and 
patency assessment of rBELs (n=5). To this end, rBELs were implanted with end-to-side 
anastomoses between the graft’s and recipient pig’s portal veins (Fig. 3b, d–i). Prior to 
perfusing the rBELs, Portal branches supplying the pig’s native liver were tied off 
preserving the first portal branch supplying the caudate lobe and the right lateral lobe. A 
constriction ribbon was also applied to the pig’s portal vein distal to the anastomosis to 
partially bias flow through the rBEL. These measures were taken to raise the portal pressure 
and facilitate preferential blood flow to the implanted rBELs. The portal vein surgical model 
provided mean venous pressure of 8.4 ± 2.2 mmHg (n=5) (mean +/− s.d.) and mean blood 
flow rates of 414 ± 16.7 ml/min (n=5) (mean +/− s.d.). rBELs were implanted and monitored 
for 30 minutes with inflow and outflow confirmation via Doppler ultrasound (Fig. 3j). 
Vascular perfusion was assessed through direct measurement 30 minutes after anastomosis 
through direct volumetric measurement of outflow blood for 60 seconds, which was 
subsequently returned to the circuit. PGCR >30 mg/h demonstrated >100 ml/min of 
perfusion after 30 minutes in 3 of 4 rBELs (Fig. 3k) further confirming the correlation 
between PGCR and in vivo graft patency.
Long-term in vivo perfusion in an immunosuppressed porcine liver transplant model
To assess long-term patency in vivo, rBELs were implanted utilizing the previously 
described auxiliary liver transplantation model (Fig. 3b, Supplementary Movie S1) and 
recipient animals were recovered without the addition of post-operative anti-platelet or anti-
coagulation therapies. To determine the impact of a host immune response directed toward 
the HUVEC-component of the rBELs on eventual graft failure, recipient animals were 
divided into two cohorts (n=4 per condition) One group underwent an immunosuppressive 
therapy regimen, and the other received no additional treatment (Excluded were 3 additional 
non-immunosuppressed implants and one additional immunosuppressed implants that 
experienced immediate – within 24 hours–graft loss attributable to surgical complications). 
In the immunosuppressed group prior to rBEL implantation, surgical splenectomy was 
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performed, and intravenous methylprednisolone was administrated at 500 mg with 
subsequent daily doses of 500 mg, 250 mg, 250 mg, 125 mg, 125 mg, 80 mg, 60 mg, 40 mg, 
30 mg and 20 mg (Fig. 4a). CT imaging with intravenous contrast was performed post-
operatively on days 0, 1, 3, 7, 10, 15, and 20 to assess the extent of perfusion through the 
rBELs (Fig. 4a–c). Perfusion following each CT imaging time point was quantified through 
computed tomography volumetric measurements using SIEMENS MultiModality 
Workstation Software. Graft volume was manually marked and the perfused area was auto 
detected through Hounsfield threshold cutoff. 3D reconstruction was performed using 
TeraRecon medical imaging software as well as the assistance of 3D visualizations created 
with Analyze24 (Fig. 4b, Supplementary Movie S2). The percentage of the reduction in 
perfusion of the rBELs from baseline postoperative CT scan was calculated and plotted (Fig. 
4d, Supplementary Fig. S4). In the absence of immunosuppression, all four implanted rBELs 
lost >85% of their initial perfusion by day 7 post-transplant. In contrast, the 
immunosuppressed group had significantly longer graft perfusion and vascular patency 
when compared to the group without immunosuppression, 8.5 [7–15] (Median [Range]) 
versus 3 [1–7] days; p=0.037, and 11 [7–20] versus 3 [1–7] days; p=0.037, respectively 
(Supplementary Table S1). Complete blood count (CBC), liver function, renal function and 
coagulation factors were followed pre-operatively as well as at post-operative days 1, 3, 7, 
10, 15, and 20 (Supplementary Table S2). One rBEL was harvested from an 
immunosuppressed recipient animal at day 7 for histological analysis which demonstrated 
persistence of the HUVEC populations in the graft (Supplementary Fig. S3a, b). The other 3 
grafts were monitored by CT imaging until total loss of graft perfusion, which was observed 
on days 10, 15, and 20, respectively. Total loss of porto-venous flow was seen on days 10, 20 
while one graft continued to have some portal-venous flow through the graft despite total 
loss of parenchymal perfusion (Fig. 4d). Evidence of rBEL perfusion was present in all of 
the grafts in the immunosuppressed group at day 7, demonstrating a significant increase in 
sustained perfusion over the non-immune suppressed group (p=0.01).
Early immune response to rBEL xenotransplantation
The native pig immune response to HUVEC cells was characterized to confirm if the high 
rate of graft failure between Days 3 and 7 was associated with an immune response to the 
HUVECs used to revascularize the rBELs. Pig serum was collected at each CT scan and 
incubated with HUVEC cultures to perform a complement mediated cytotoxicity assay25. 
Complement mediated cytotoxicity reaction was observed between naïve pig sera and 
HUVECs at baseline (range 30–85% cell death) demonstrating an inherent immune response 
to the human-derived cells without graft exposure in both no treatment and 
immunosuppressed groups (Fig. 4e). Evidence of an in vivo complement activation was 
observed by C4D deposition on endothelial cells in explanted rBEL samples (Supplementary 
Fig. S3c).
Cytotoxicity significantly increased in the no treatment by Day 3 (81.7 ± 21.0) (mean +/− 
s.d.) and remained at >98% following Day 3. In contrast, immunosuppression significantly 
reduced cytotoxicity at Day 1 and Day 3 25.2 (±29.4), and 8.68 (±8.49) respectively, 
followed by a notable increase in cytotoxicity at day 7 84.7 (±13.0) and >98% cytotoxicity 
at Day 10 and Day 15 (Fig 4e). rBEL perfusion in the no treatment and immunosuppression 
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groups correlated to cytotoxicity responses. Decreased rBEL perfusion was preceded by a 
significant increase in an immune response as seen on Day 3 for no treatment and Day 7 for 
the immunosuppressed group (Fig 4d, e).
Discussion
The only cure for ESLD, the 8th most frequent cause of death in the United States, is liver 
transplantation. Unfortunately, the demand for transplantable donor livers continues to 
exceed the available supply, and as a result, only half of the 11,000 wait-listed patients will 
receive transplants26. Globally, it is estimated that over 1 million patients could benefit from 
a liver transplant27. The insufficient supply in transplantable donor livers underscores the 
need for alternative strategies to generate functional liver tissue for patients suffering from 
liver failure.
Efforts to overcome the chronic shortage of transplantable human livers include attempts at 
alternative organ procurement and replacement strategies28. Xenogeneic whole organ 
transplantation promises a theoretically limitless supply of donor organ material, but 
immunological incompatibility, fundamental differences in basal metabolism between 
humans and other species, and coagulopathy remain significant translational barriers6,17,29. 
Hepatocyte transplantation represents a currently approved alternative to whole organ 
replacement; however, poor cell engraftment efficiency and deterioration of cell function 
over time has largely relegated this to a bridge therapy and temporary metabolic support 
ahead of whole liver transplantation30.
Tissue engineering remains a promising solution to the chronic organ shortage but has been 
significantly inhibited by lack of functional vasculature required to support implantation of 
engineered tissue similar to donor grafts. Whole organ perfusion decellularization and 
recellularization technologies have demonstrated the ability to maintain the native 
architecture and have demonstrated organ function from the recellularization of liver6,31,32, 
kidney33,34 and lung35, However, none have demonstrated the ability to sustain long-term in 
vivo perfusion because of incomplete vasculature, a critical component to move the field 
forward.
The daily measurement and analysis of metabolic markers, specifically daily GCRs, 
provided the opportunity for critical adjustments for bioreactor media volume and provided 
growth parameters that were evaluated as surrogates for re-endothelialization. PGCR not 
only indicates the level of rBEL endothelialization in culture.36, but is also predictive of in 
vivo performance. The resulting function of the rBEL was independent of days in culture, 
but instead dependent upon metabolic activity. It appears that these phases correlated with 
increased endothelial coverage starting in the larger vessels followed by proliferation and 
migration into the parenchymal space during mid and high GCR phases. The defined PGCR 
levels were characterized for 250 to 350g livers and it is expected that moving to larger 
livers will require a higher minimum PGCR threshold.
During this time, LYVE1 expression and localization was increased in the parenchymal 
space, with little expression in larger vessels, the inverse was observed with the localization 
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of CD31, suggesting a degree of phenotypic plasticity of HUVECs within the decellularized 
liver scaffold. Global gene expression via RNA-seq analysis on isolated rBEL sections 
characterized a shift in gene expression between low and high glucose consuming rBELs 
and revealed additional gene expression trends consistent with an LSEC-like phenotype. To 
provide physical evidence of fenestrations, a key hallmark of LSECs, TEM evaluation of 
rBELs exhibited fenestrae-like features similar in size to those observed in native liver 
sections. The combined molecular analysis and microscopic examination support the shift 
towards an LSEC-like phenotype and will need to be further characterized following the 
addition of hepatocytes and cholangiocytes to the rBELs.
To assess the deleterious effects of a host immune response to human cells, a detection of the 
xeno-compatibility phenomenon between pig serum and human cells was employed. A non-
sophisticated 10-day immunosuppression protocol was used to demonstrate the ability to 
increase the vascular perfusion of the rBELs from, on average, 3.5 days up to 15 days and 
extended the patency of the vascular tree beyond 15 days. The immunosuppression protocol 
used in this study was not intended to provide long-lasting immunosuppression, but rather to 
determine whether a species-dependent immunological response was contributing to the loss 
of graft perfusion. Vascular patency was prolonged using the immunosuppression regimen 
indicating that xeno-incompatibility played a significant role in eventual rBEL thrombosis in 
vivo. Following immunosuppression withdrawal, similar kinetics for graft thrombosis to the 
non-immunosuppressed group were observed. Vascular patency in the humanized 
bioengineered liver grafts would have likely been sustained longer with continued 
immunosuppressive therapy.
In this study, we demonstrate an ability to produce rBEL constructs with functional 
vasculature that can retain long-term in vivo vascular patency leading to definitive functional 
testing of co-seeded whole liver grafts with parenchymal hepatocytes and cholangiocytes. 
Adequate endothelization is sufficient to prevent vascular thrombosis thus providing a path 
forward to engineering a fully functional transplantable liver.
Methods
Decellularization of porcine livers.
Whole livers (250 to 350 grams) were excised from cadaveric pigs. The Suprahepatic Vena 
Cava (SVC), Inferior Vena Cava (IVC), Portal Vein (PV), and Bile Duct were cannulated 
and flushed with 150 ml of sterile saline. The cannulated livers were perfusion 
decellularized with 1× Triton X-100 (Amresco, M143) for 2–5 hours followed by 0.6% 
sodium dodecyl sulfate (Amresco, 0227) for 4–8 hours at a perfusion pressure maintained 
between 8–12 mmHg. The decellularized livers were disinfected with 1000 ppm peracetic 
acid (PAA; U.S. Water, BI0032–6). The decellularized grafts were washed with phosphate 
buffered saline (PBS; Corning 21–040-CMX12) and stored. All decellularization was 
completed in an ISO 7 cleanroom. Decellularization and recellularization utilized a custom-
built perfusion system to automatically adjust flow to maintain a defined pressure utilizing 
Cole-Palmer peristaltic pumps (7575–30, 77200–60).
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Decellularization and recellularization utilized a custom-built perfusion system to 
automatically adjust flow to maintain a defined pressure utilizing Cole-Palmer peristaltic 
pumps (7575–30, 77200–60).
HUVEC cell culture and seeding of decellularized liver constructs.
Human umbilical vein endothelial cells (Lonza, C2517A) were cultured in antibiotic-free 
EGM-2 (Lonza, CC-3162) medium in tissue culture flasks (Falcon) at 37°C and 5% CO2 
and passaged with 0.25% trypsin (Thermo, 25200056) at 90–100% confluency according to 
manufacturer’s protocol. The highest passage used for seeding liver grafts was passage 11.
The medium used for HUVEC culture was also used for seeding and maintaining re-
vascularized liver constructs in this study. Decellularized porcine livers were placed in a 
custom bioreactor containing 800ml of media, connected to the perfusion inlet via the SVC, 
and perfused at 12 mmHg with culture media prior to seeding. 1.5×108 HUVECs were re-
suspended in 100 ml of media and seeded through the SVC followed by 50 ml of fresh 
media to clear the measured tubing void volume. The infused cell suspension was left under 
static conditions for one hour and then continuous perfusion was restarted. After 24 hours, 
perfusion was changed from the SVC to the PV and the seeding protocol was repeated with 
an additional1.5×108 HUVECs. Re-endothelialized grafts were maintained in a continuous 
perfusion loop with metabolites (glucose, lactate, glutamine, glutamate and ammonia) 
monitored daily in collected media samples using a BioProfile FLEX analyzer (Nova 
Biomedical). Culture media was exchanged and the volume increased depending on the rate 
of glucose depletion in the circulating medium to ensure 24 hour glucose levels above 500 
mg/L. All liver bioreactors were cultured in a humidified 37⁰C incubator with 5% CO2.
Histological Analysis.
Tissue samples analyzed in this study were perfused with PBS and fixed with 10% Neutral 
Buffered Formalin (VWR 16004–128). Fixed tissues were paraffin embedded, sectioned and 
stained using standard histologic techniques. Immunofluorescence slides were 
deparaffinized, rehydrated and retrieval was performed in citrate buffer, pH 6.0 (Abcam 
AB93678) in a programmable decloaker (Biocare DC2012). Slides were permeabilized with 
PBS + 0.05% Tween-20 (Sigma P9416) and blocked with Sea Block (Thermo 37527). 
Primary antibodies used included mouse anti-CD31 (Abcam AB187377), rabbit anti-
Collagen I (Abcam AB34710), rabbit anti-LYVE1 (Abcam AB33682), and mouse anti-C4D 
(Abcam AB90804). Secondary antibodies used were goat anti-rabbit Alexa Fluor 488 
(Thermo A11078), goat anti-mouse Alexa Fluor 488 (Thermo A11029), and goat anti-rabbit 
Alexa Fluor 555 (Thermo A21429). Slides were stained with 4’,6-diamidino-2-phenylindole 
(Thermo D1306) diluted 1:200 in PBS and mounted using ProLong Antifade Mountant 
(Thermo P36961). Fluorescence slides were imaged on a Zeiss Axioskop 40 and H&E slides 
were imaged on an Accuscope 3012.
Transmission Electron Microscopy.
Tissue was fixed with 4% paraformaldehyde + 1% glutaraldehyde fix in phosphate buffered 
saline, pH 7.2. Following fixation, cells were stained with 1% osmium tetroxide and 2% 
uranyl acetate, dehydrated through an ethanol series and embedded into Embed 812 resin. 
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After a 24 h polymerization at 60°C, 0.1 μm ultrathin sections were post-stained with lead 
citrate. Micrographs were acquired using a JEOL1400+ transmission electron microscope 
(Peabody, MA) operating at 80kV with a Gatan Orius camera and Digital Micrograph 
software (Pleasanton, CA).
RNA extraction and quantitative reverse-transcription PCR (qRT-PCR).
RNA isolation was performed using TRIzol Reagent (Thermo Fisher) and transcribed to 
cDNA using the Superscript III First-Strand Synthesis System (Invitrogen). Gene expression 
analysis was performed using the Platinum SYBR green qRT-PCR supermix-UDG kit 
(Invitrogen) in a ViiA 7 Real-Time PCR instrument (Thermo Fisher Scientific). Ribosomal 
protein L19 (RPL19) was used as a housekeeping gene for normalization. The following 
primer sets were used in this study: RPL19 5’ATTGGTCTCATTGGGGTCTAAC3’, 
5’AGTATGCTCAGGCTTCAGAAGA3’; STAB2 
5’GCAAGAAGATGTGATAGGAAGTCTC3’, 5’ACAACACCGAGGTTGGAGAT3’, 
LYVE1 5’TTTGCAGCCTATTGTTACAACTCAT3’, 5’GGGATGCCACCCAGTAGGTA3’ 
and CD31 5’TCTGCACTG CAGGTATTGACAA, 5’CTGATCGATTCGCAACGGA3’.
RNA-seq analysis.
Tissue samples from low GCR (n=2) and high GCR (n=6), along with HUVECs (n=1) and 
human LSECs (Cell Systems, ACBRI 566) (n=1) were processed for RNA-seq analysis. 
RNA isolation was performed using TRIzol Reagent (Thermo Fisher). mRNA isolation for 
all samples was performed using the Direct-zol RNA Miniprep Kit (Zymo Research) and 
quantified using a NanoDrop 2000 spectrophotometer (Thermo Fisher).
Samples were assessed for RNA integrity (RIN) using the Agilent Bioanalyzer DNA 1000 
chip (Invitrogen). Only samples with RIN scores > 6 and DV200 > 50% were selected for 
sequencing. RNA-sequencing and subsequent primary and secondary data analysis was 
performed as previously described37,38. In brief, library preparation was performed using the 
TruSeq RNA library preparation kit (Illumina). Polyadenylated mRNAs were selected using 
oligo dT magnetic beads. TruSeq Kits were used for indexing to permit multiplex sample 
loading on the flow cells and paired-end sequencing reads were generated on the Illumina 
HiSeq 2000 sequencer. Quality control for concentration and library size distribution was 
performed using an Agilent Bioanalyzer DNA 1000 chip and Qubit fluorometry 
(Invitrogen). Sequence alignment of reads and determination of normalized gene counts 
were performed using the MAP-RSeq (v.1.2.1) workflow, utilizing TopHat 2.0.639, and 
HTSeq40. Normalized read counts were expressed as reads per kilobasepair per million 
mapped reads (RPKM).
All genes with an average expression > 0.3 RPKM in at least one group (n=12,944) were 
utilized for subsequent analyses. Principal Component Analysis (PCA) was performed using 
ClustVis online tool41. Similarity matrix and hierarchical clustering analysis was performed 
using Morpheus matrix visualization and analysis (Morpheus, https://
software.broadinstitute.org/morpheus, Broad Institute). Functional annotation and Gene 
Ontology (GO) term enrichment scores were calculated using DAVID Bioinformatics 
Resources 6.8 database (DAVID 6.8)42. Results from the DAVID analysis (Supplementary 
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Dataset 1), a list of upregulated genes (Supplementary Dataset 2), and a list of input genes 
used for the similarity matrix analysis (Supplementary Dataset 3) are included in the 
Supplementary Materials.
Acute blood flow studies.
For in vitro blood perfusion studies, each rBEL was connected to a circuit composed of 
silicone tubing, a pressure transducer, and a peristaltic pump. Recirculation of freshly 
harvested, 37°C heparinized porcine blood was targeted at 9–12 mmHg to mimic maximum 
physiologically achievable venous pressure and resulting flow rates were monitored over 
time.
In vivo acute blood studies were performed using domestic pigs weighing 30–35 kg. rBEL 
construct were connected to portal venous blood flow using silicone tubing and luer-lock 
connectors to achieve functional end-to-side anastomoses between the graft’s and recipient 
animal’s portal veins and IVCs. Luer lock connectors allowed for direct measurement of 
blood flow with and without the rBEL in the circuit. Flow was assessed through direct 
measurement of collected outflow blood for 60 seconds, which was subsequently returned to 
the circuit. Post-test graft venogram through the PV was performed to ensure the patency of 
the portal vascular tree using 15–20 ml of Omnipaque 3000. Intravenous (IV) heparin was 
used to maintain an activated clotting time (ACT) > 600 seconds throughout the procedure.
Long-term studies to assess graft perfusion and vascular patency.
Grafts with >30 mg/h GCR were selected for transplantation in all long term in-vivo 
perfusion studies. All animal experiments were performed in accordance with the Animal 
Welfare Act and approved by the institutional animal care and use committee at Mayo 
Clinic. Heterotopic implantation of rBELs in this study relied on end-to-side anastomoses 
between the graft’s and recipient animal’s PV, and the graft’s and recipient animal’s IVC. 
All portal branches supplying the animal’s native liver with the exception of the first branch 
were tied off, thereby preserving blood flow to the caudate lobe and the right lateral lobe. 
Additionally, a constricting ribbon was applied surgically around the native portal vein distal 
to the anastomosis to enhance blood flow to the implanted rBEL. This sequence was 
followed to elevate the portal vein pressure while avoiding hemodynamic instability 
resulting from host portal vein clamping and abrupt cessation of portal flow.
The surgical procedure was performed under normal hemostasis without the use of systemic 
heparinization. Side clamping of the pigs’ portal vein and vena cava were performed to 
allow the anastomoses to be fashioned while minimizing the risk of thrombosis. After the 
procedure, the pigs were monitored in a recovery cage for the first 24 hours and assessed 
every 4–6 hours for any signs of bleeding or immediate surgical complications. Pigs were 
allowed to drink during this period as tolerated. Subsequently they were allowed to return to 
the regular housing and allowed regular diet as tolerated.
Operative data included OR time, cold ischemia time, ACT, liver function test (LFT), 
complete blood count (CBC), and coagulation factors. Cytotoxicity profile were followed 
pre-operatively as well as at post-operative days 1, 3, 7, 10, 15, and 20. To evaluate vascular 
patency and graft perfusion, contrast enhanced computed tomography (CT) scans were 
Shaheen et al. Page 11













performed serially postoperatively following the same time points listed above. All scans 
included a dedicated porto-venous phase taken 50–60 seconds after contrast infusion.
All pigs were followed until graft thrombosis was ascertained via contrast enhanced CT 
scans, except for one pig in the immunosuppressed group which was intentionally 
euthanized at Post-Operative day 7 for the purpose of obtaining histopathological data of the 
graft at that time.
Volumetric analysis of the graft perfusion and vascular patency of the large vessels was 
calculated using Siemens MultiModality Workstation software. Perfused areas were 
automatically detected through Hounsfield density cutoff threshold. Subsequent loss of 
perfusion was calculated over time, at day 1, 3, 7, 15 and 20. Loss of graft perfusion was 
defined by absence of notable perfusion outside the major portal branches and hepatic veins. 
Complete loss of perfusion and vascular patency was defined by a clear loss of flow in the 
graft’s portal vein branches. Given the plasticity of the rBEL, the volume was affected in 
cases of ileus or gastric distension which sometimes occurred in the first 3–5 days after 
surgery.
Serum cytotoxicity assay.
The complement-based cytotoxicity assay was adapted from a previously described 
protocol25. Briefly, 48-well tissue culture plates were seeded with 1×105 HUVECs/well and 
incubated at 37°C until 80–100% confluence was reached (24–48 hours). Following an 
initial PBS wash, pig sera were diluted 1:32 with EGM-2 media and 200 μl of diluted pig 
sera were added to each well. Following 30 minutes of incubation at room temperature, 
wells were washed with PBS, and 200 μl of unabsorbed rabbit complement (Pel-Freez) 
diluted 1:16 with EGM-2 media was added to each well and incubated at room temperature 
for 1 hour. 2 μl of 1% Fluoroquench (Thermo Fisher) was added for fluoroscopic assessment 
of viable and nonviable cells. Cytotoxicity was characterized by the resulting percentage of 
nonviable cells.
Statistical Analysis.
IBM SPSS Software version 25 was used to conduct the statistical analysis. Descriptive data 
are presented as mean +/− Standard deviation. For subsets of data that did not meet 
normality tests, the median and [range] were used. Correlations between graft flow and 
metabolic parameters were statistically compared using binary correlation and linear logistic 
regression. Surgical model parameters, duration of graft perfusion, and vascular patency 
between immunosuppressed and non-immunosuppressed animals were compared using a 
Student’s t-test. Mann-Whitney test was alternatively used for subsets of data that are not 
normally distributed with a Shaprio-Wilk’s tests of (P<0.05).
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. Porcine liver decellularization and perfusion bioreactor system.
(a) Native porcine livers are cannulated on the PV, IVC and SVC, and decellularized by 
sequential perfusion with Triton X-100 and SDS solutions. (b-g) Representative 
photographs, H&E staining and Collagen I immunofluorescence of native (b-d) and 
decellularized (e-g) porcine livers. (h, i) Schematic (h) and photo (i) of perfusion bioreactor 
system comprised of a custom bioreactor and a pressure-dependent perfusion control 
system. The bioreactor includes a pressure transducer (PT) to monitor perfusion pressure, a 
gas exchange coil (GEC) to allow efficient gas exchange during media perfusion, a bubble 
trap (BT) to prevent the introduction of bubbles into the rBEL, a 0.22 μm filter air vent (AV), 
and three-way stopcocks (3W) to enable media exchange and sampling.
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Figure 2. Analysis of rBEL culture kinetics and HUVEC phenotypic plasticity in decellularized 
liver matrix.
(a) HUVECs are expanded in 2D tissue culture flasks, harvested and seeded through the 
graft SVC, followed by the PV 24 hours later. (b) Representative CD31+ flow cytometry 
demonstrating a phenotypically pure HUVEC population immediately prior to graft seeding. 
(c) Plots of glucose consumption rates over time from independently seeded and cultured 
rBEL constructs (n=14). Peak glucose consumption rates correlated with total endothelial 
cell coverage as characterized by H&E staining (d-f) and anti-CD31 immunostaining (g-i). 
(j) Quantitative RT-PCR analysis of CD31, LYVE1 and STAB2 mRNA levels in rBELs 
harvested at low (n=4), mid (n=4) and high (n=7) glucose consumption phases Data are 
plotted as fold change relative to HUVECs in 2D culture. Individual values represent 
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biological replicates. Mean values ± standard deviation are shown. Statistical significance 
was determined using a one-way ANOVA test from dCT values prior to fold-change 
normalization. (k-m) CD31 and LYVE-1 immunostaining from rBELs harvested at low, mid 
and high glucose consumption phases.(n) Principal component analysis of RNA-seq gene 
expression profiles from rBELs harvested at low (n=2 biological replicates) and high (n=6 
biological replicates) glucose consumption phases. (o) Similarity matrix of BEL samples 
from (n) comparing low and high glucose consumption phase rBEL samples with respect to 
panel of known liver endothelial cell markers (input genes: F8, CD31, STAB2, LYVE1, 
CD14, VWF, ENG, ICAM1).(p) RNA-seq expression profiles for liver sinusoidal 
endothelial markers LYVE1, VWF, and ICAM1 in low (n=2) and high (n=6) glucose 
consumption phase rBEL samples. HUVECs (n=1) and primary human LSECs (n=1) 
cultured in 2D are included for comparison. Biological replicates are plotted along with the 
mean ± standard deviation. (q-t) TEM images from native liver (q) and rBEL (r-t) samples. 
Red arrows indicate fenestrae-like structures within endothelial cells.
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Figure 3. In vitro and in vivo patency correlates with peak glucose consumption rate.
(a, c) Diagram and setup of the in vitro blood circuit used to evaluate rBEL patency. The 
circuit perfuses a rBEL with warm, heparinized whole porcine blood and is driven by a 
peristaltic pump controlled by a pressure-based custom control system. (b) Illustration of in 
vivo heterotopic liver implant model where the rBEL is anastomosed via the PV and IVC to 
the native PV and IVC. Partial flow was given to both the rBEL and the native liver by 
restricting flow to the native liver. (d-i) Representative images of the heterotopic liver 
implant including graft preparation, anastomosis and reperfusion. (j) Representative 
ultrasound images of an implanted rBEL demonstrating portal and hepatic veinous flow after 
30 min. (k) Flow rates from in vitro (n=5) and in vivo (n=5) perfusion studies. Values from 
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independent rBELs are plotted. Peak glucose consumption of >30 mg/h correlates with >100 
mL/min of blood flow in vitro and in vivo.
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Figure 4. Long term in vivo perfusion studies in the presence and absence of immunosuppression.
(a) In vivo implants were separated into two groups: no treatment and immunosuppression. 
The immunosuppression group received a methylprednisolone immunosuppression dose 
(I.D.) starting at 500 mg on Day 0 and was tapered over ten days. (b) 3D CT reconstruction 
after graft implantation showing the heterotopic position of the implanted graft below the 
native liver while demonstrating good vascular perfusion of the implanted graft. (c) Serial 
contrast enhanced CT images of the implanted bioengineered liver grafts over time. Grafts 
are highlighted with dotted lines. Yellow dotted lines delineate perfused graft with contrast 
in white. Red dotted lines reflect no parenchymal perfusion. (d) Quantification of graft 
perfusion reduction over time in untreated (n=4) and immunosuppressed (n=4) animals. (e) 
Cytotoxicity of pig sera from untreated (n=4) and immunosuppressed (n=4) animals 
incubated on in vitro HUVEC cultures following addition of unabsorbed rabbit complement.
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